Semler Scientific(US:SMLR) Prnewswire·2025-06-24 12:00Company Overview - Semler Scientific, Inc. is the second U.S. public company to adopt Bitcoin as its primary treasury reserve asset and is a leader in medical devices and software aimed at combating chronic diseases [1][3] - The company has announced the formation of CardioVanta, Inc., a wholly-owned subsidiary focused on early detection of heart failure and cardiac arrhythmia monitoring [1][3] Business Model and Strategy - CardioVanta will operate under a high-margin, software-as-a-service (SAAS) business model and will seek external capital to validate its long-term value and fund initial capital needs [1] - The markets for early detection of heart failure and cardiac arrhythmia monitoring are projected to grow substantially, driven by factors such as rising cardiovascular diseases, technological advancements, and an aging population [1] Market Potential - The market for early detection of heart failure and cardiac arrhythmia monitoring is estimated to be in the multibillion-dollar range [1] - Heart failure affects over six million Americans and costs the U.S. healthcare system more than $30 billion annually, highlighting the significant market opportunity [1] Product Offerings - Semler Scientific's flagship product, QuantaFlo, is a patented device cleared by the U.S. Food and Drug Administration (FDA) that provides rapid point-of-care testing for peripheral artery disease [3] - The company will continue to market the QuantoFlo® device while expanding its healthcare business through CardioVanta [1][3] Leadership Vision - The chairman of Semler Scientific emphasized the strategic plan as an opportunity to enhance the company's ability to combat chronic diseases and increase Bitcoin holdings, aiming to drive stockholder value [2] - The CEO highlighted the mission to empower individuals with both monetary freedom through Bitcoin and advanced healthcare solutions [2]